Biotech News

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

Ironwood Pharmaceuticals (IRWD)Ironwood Pharmaceuticals2022-09-06 11:00 ESTClinical readout

IRWD (IRWD) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is irwd.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a gastrointestinal-focused company anchored by Linzess and a pipeline aimed at digestive health. Its story is centered on GI commercialization and pipeline extension.

Recent company news

IRWDIronwood Pharmaceuticals2026-08-06 11:05 EST

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

IRWDIronwood Pharmaceuticals2026-07-30 20:05 EST

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

IRWDIronwood Pharmaceuticals2026-07-14 11:30 EST

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

IRWDIronwood Pharmaceuticals2026-05-28 20:05 EST

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

IRWDIronwood Pharmaceuticals2026-05-27 14:00 EST

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

Stock data

Close: 4.26 USD
Market cap: 539.93M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States